Open AccessP784: A PHASE I/II STUDY OF VENETOCLAX IN COMBINATION WITH ASTX727 (DECITABINE/CEDAZURIDINE) IN TREATMENT‐NAÏVE HIGH‐RISK MYELODYSPLASTIC SYNDROME (MDS) OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
Author(s) -
Venugopal S.,
kantarjian H.,
Maiti A.,
Short N.,
MontalbanBravo G.,
Alvarado Y.,
Chien K. S.,
KanagalShamanna R.,
Pemmaraju N.,
Daver N.,
Kadia T.,
Borthakur G.,
Jabbour E.,
GarciaManero G.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846020.01506.f5
Subject(s) - decitabine , medicine , tolerability , venetoclax , ven , azacitidine , population , regimen , oncology , chronic myelomonocytic leukemia , myelodysplastic syndromes , neutropenia , phases of clinical research , international prognostic scoring system , adverse effect , gastroenterology , leukemia , bone marrow , chronic lymphocytic leukemia , clinical trial , chemotherapy , biochemistry , gene expression , chemistry , computer security , environmental health , computer science , dna methylation , gene